Lin Bo, Ma Ying-Yu, Wang Jun-Wei
Urology & Nephrology Center, Department of Nephrology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, China.
Key Laboratory of Gastroenterology of Zhejiang Province, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, China.
Front Bioeng Biotechnol. 2022 May 13;10:870049. doi: 10.3389/fbioe.2022.870049. eCollection 2022.
Diabetic nephropathy (DN) is the leading cause of end-stage renal disease worldwide. With the rising prevalence of diabetes, the occurrence of DN is likely to hit pandemic proportions. The current treatment strategies employed for DN focus on the management of blood pressure, glycemia, and cholesterol while neglecting DN's molecular progression mechanism. For many theranostic uses, nano-technological techniques have evolved in biomedical studies. Several nanotechnologically based theranostics have been devised that can be tagged with targeting moieties for both drug administration and/or imaging systems and are being studied to identify various clinical conditions. The molecular mechanisms involved in DN are discussed in this review to assist in understanding its onset and progression pattern. We have also discussed emerging strategies for establishing a nanomedicine-based platform for DN-targeted drug delivery to increase drug's efficacy and safety, as well as their reported applications.
糖尿病肾病（DN）是全球终末期肾病的主要原因。随着糖尿病患病率的上升，DN的发生可能会达到流行程度。目前用于DN的治疗策略侧重于血压、血糖和胆固醇的管理，而忽视了DN的分子进展机制。在许多治疗诊断应用中，纳米技术已在生物医学研究中得到发展。已经设计了几种基于纳米技术的治疗诊断方法，这些方法可以标记靶向部分用于药物给药和/或成像系统，并且正在进行研究以识别各种临床病症。本综述讨论了DN涉及的分子机制，以帮助理解其发病和进展模式。我们还讨论了建立基于纳米医学的平台用于DN靶向药物递送以提高药物疗效和安全性的新兴策略及其报道的应用。
